Abstract
Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant therapy with the aromatase inhibitor letrozole after tamoxifen reduces the risk of such late recurrences, was stopped early after an interim analysis showed that letrozole improved disease-free survival. This report presents updated findings from the trial.
Original language | English |
---|---|
Pages (from-to) | 1262-71 |
Number of pages | 10 |
Journal | Journal of the National Cancer Institute (JNCI) |
Volume | 97 |
Issue number | 17 |
DOIs | |
Publication status | Published - 7 Sept 2005 |
Keywords / Materials (for Non-textual outputs)
- Aged
- Antineoplastic Agents, Phytogenic
- Antineoplastic Combined Chemotherapy Protocols
- Aromatase Inhibitors
- Breast Neoplasms
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Female
- Humans
- Incidence
- Lymphatic Metastasis
- Middle Aged
- Nitriles
- Postmenopause
- Receptors, Estrogen
- Receptors, Progesterone
- Survival Analysis
- Tamoxifen
- Treatment Outcome
- Triazoles